Kelun-Biotech's Innovative ADC SKB315 Approved for Gastric Cancer Treatment in China Kelun-Biotech announces the approval of SKB315, a groundbreaking ADC combined with tagitanlimab, for gastric cancer treatment in China.

Kelun-Biotech's Innovative ADC SKB315 Approved for Gastric Cancer Treatment in China #China #Chengdu #Kelun-Biotech #Tagitanlimab #SKB315